对于日常实践中持续演进的eHealth工具的改善和实施情况尚不清楚。CMyLife数字护理平台通过赋予慢性髓系白血病患者权力，以使药物依从性洞察性、可讨论性和最佳化为重点，实现对生物标志物BCR-ABL1的最佳控制。本研究的目标是调查参与行动研究方法在日常临床实践中改进和科学评估eHealth创新的适用程度（通过用户体验来衡量），同时促进患者的赋权。研究采用了规划、行动和反思的迭代循环，参与者（患者、医疗保健提供者、CMyLife团队和应用程序供应商）的平台经验决定了下一步的行动。共同设计研讨会是这个循环过程的基础。此外，患者需在3个月和至少6个月后填写2组问卷，以评估他们对CMyLife的体验、平台的实际使用情况以及平台的影响。通过对研讨会期间收集的数据进行内容分析来进行分析，内容分析通常用于指导实际操作。描述性统计方法用于描述研究人口的慢性髓系白血病相关信息和社会人口学情况，以及对CMyLife数字护理平台和实际使用情况的体验。共同设计研讨会提供的见解有助于改进、实施和评估CMyLife，赋予患有慢性髓系白血病的患者权力（例如，语言简化和功能的用户友好性改进）。问卷调查结果显示：（1）该平台改善了67%（33/49）的患者对慢性髓系白血病信息的提供情况，（2）药物应用的使用改善了42%（16/38）的患者的药物依从性，（3）指南应用的使用改善了44%（11/25）的患者对指南的遵循情况，以及（4）平台的使用使患者感到更有权力。参与行动研究方法适合在日常临床实践中科学评估数字护理平台的改进、实施和患者赋权。需要对用户需求和愿望进行系统迭代评估，以保持关注患者的护理，并使创新保持最新和对用户有价值。©Lynn Verweij，Sanne JJPM Metsemakers，Geneviève IC G Ector，Peter Rademaker，Charlotte L Bekker，Bas van Vlijmen，Bert A van der Reijden，Nicole M A Blijlevens，Rosella PMG Hermens。最初发表于《医学互联网研究》（https://www.jmir.org），2023年9月15日。

The evaluation of a continuously evolving eHealth tool in terms of improvement and implementation in daily practice is unclear. The CMyLife digital care platform provides patient-centered care by empowering patients with chronic myeloid leukemia, with a focus on making medication compliance insightful, discussable, and optimal, and achieving optimal control of the biomarker BCR-ABL1.The aim of this study was to investigate to what extent the participatory action research approach is suitable for the improvement and scientific evaluation of eHealth innovations in daily clinical practice (measured by user experiences) combined with the promotion of patient empowerment.The study used iterative cycles of planning, action, and reflection, whereby participants' experiences (patients, health care providers, the CMyLife team, and app suppliers) with the platform determined next actions. Co-design workshops were the foundation of this cyclic process. Moreover, patients filled in 2 sets of questionnaires for assessing experiences with CMyLife, the actual use of the platform, and the influence of the platform after 3 and at least 6 months. Data collected during the workshops were analyzed using content analysis, which is often used for making a practical guide to action. Descriptive statistics were used to characterize the study population in terms of information related to chronic myeloid leukemia and sociodemographics, and to describe experiences with the CMyLife digital care platform and the actual use of this platform.The co-design workshops provided insights that contributed to the improvement, implementation, and evaluation of CMyLife and empowered patients with chronic myeloid leukemia (for example, simplification of language, and improvement of the user friendliness of functionalities). The results of the questionnaires indicated that (1) the platform improved information provision on chronic myeloid leukemia in 67% (33/49) of patients, (2) the use of the medication app improved medication compliance in 42% (16/38) of patients, (3) the use of the guideline app improved guideline adherence in 44% (11/25) of patients, and (4) the use of the platform caused patients to feel more empowered.A participatory action research approach is suited to scientifically evaluate digital care platforms in daily clinical practice in terms of improvement, implementation, and patient empowerment. Systematic iterative evaluation of users' needs and wishes is needed to keep care centered on patients and keep the innovation up-to-date and valuable for users.©Lynn Verweij, Sanne J J P M Metsemakers, Geneviève I C G Ector, Peter Rademaker, Charlotte L Bekker, Bas van Vlijmen, Bert A van der Reijden, Nicole M A Blijlevens, Rosella P M G Hermens. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 15.09.2023.